[Treatment of acute leukemia by differentiation: effects of all trans retinoic acid in acute promyelocytic leukemia].
All trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia is the first model of differentiation therapy in malignancies, and represents the first strict correlation between a genetic defect and a specific treatment. In this disease the association of differentiating agents and chemotherapy gives much better results than each type of treatment (differentiating agent or chemotherapy).
Degos
L
L
Institut d'Hématologie, Hôpital Saint-Louis, Paris, France.
D001778:Blood Coagulation Disorders / Q000188:drug therapy / Q000209:etiology; D002454:Cell Differentiation / Q000187:drug effects; D004351:Drug Resistance; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000150:complications / Q000188:drug therapy*; D013577:Syndrome; D014212:Tretinoin / Q000009:adverse effects / Q000627:therapeutic use*
D014212:Tretinoin
Traitement par différenciation des leucémies aiguës: effets de l'acide tout trans rétinoïque dans la leucémie aiguë promyélocytaire.